Optimal antithrombotic treatment for percutaneous coronary intervention

Minerva Cardioangiologica

Volumn 53, Issue 1, 2005, Pages 15-42

  Kadakia, R A ^a   Ferguson, J J ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

Angioplasty coronary balloon; Antithrombotic agents; Coronary disease

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; CILOSTAZOL; CLOPIDOGREL; DALTEPARIN; DESULFATOHIRUDIN; DIPYRIDAMOLE; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRUDIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; REVIPARIN; SULFINPYRAZONE; TENECTEPLASE; THROMBIN INHIBITOR; TICLOPIDINE; TIROFIBAN; WARFARIN; DRUG DERIVATIVE; FIBRINOGEN RECEPTOR; PYRIDINE DERIVATIVE; THIENOPYRIDINE; THROMBIN;

ANTICOAGULATION; BLEEDING; BLOOD CLOTTING; BONE MARROW TOXICITY; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; EVIDENCE BASED MEDICINE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; MUSCLE NECROSIS; NEUTROPENIA; PERCUTANEOUS CORONARY INTERVENTION; RASH; REVASCULARIZATION; REVIEW; STROKE; THROMBOCYTE; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNSTABLE ANGINA PECTORIS; DRUG ANTAGONISM; DRUG EFFECT; METHODOLOGY; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; ASPIRIN; BLOOD COAGULATION; CLINICAL TRIALS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PYRIDINES; STENTS; THROMBIN; THROMBOSIS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 16244378039     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (124)

1. Mabin TA, Holmes DR Jr, Smith HC, Vlietstra RE, Bove AA, Reeder GS et al. Intracoronary thrombus: role in coronary occlusion complicating percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1985;5 (2 Pt 1):198-202.
2. Sugrue D, Holmes D Jr, Smith H, Reeder GS, Lane GE, Vlietstra RE et al. Coronary artery thrombus as a risk factor for acute vessel occlusion during percutaneous transluminal coronary angioplasty: improving results. Br Heart J 1986;56:02-6.
3. de Feyter P, van den Brand M, Jaarman G, van Domburg R, Serruys PW, Suryapranata H. Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty. Circulation 1991;83:927-36.
4. Vaitkus P, Herrmann H, Laskey W. Management and immediate outcome of patients with intracoronary thrombus during percutaneous transluminal coronary angioplasty. Am Heart J 1992;124:1-8.
5. Bergelson B, Jacobs A, Cupples A, Ruocco NA Jr, Kyller MG, Ryan TJ et al. Prediction of risk for hemodynamic compromise during percutaneous transluminal coronary angioplasty. Am J Cardiol 1992;70:1540-5.
6. Hermans W, Foley D, Rensing B, Rutsch W, Heyndrickx GR, Danchin N et al. Usefulness of quantitative and qualitative angiographic lesion morphology, and clinical characteristics in predicting major adverse cardiac events during and after native coronary balloon angioplasty. Am J Cardiol 1993;72:14-20.
7. Myler R, Shaw R, Stertzer S, Bashour TT, Ryan C, Hecht HS et al. Unstable angina and coronary angioplasty. Circulation 1990;82 (3 Suppl):II88-95.
8. Mooney M, Mooney J, Goldenberg I, Almquist AK, Van Tassel RA. Percutaneous transluminal coronary angioplasty in the setting of large intracoronary thrombi. Am J Cardiol 1990;65:427-31.
9. Ellis SG, Roubin GS, King III SB, Douglas JS Jr, Weintraub WS, Thomas RG et al. Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty. Circulation 1988;77:372-9.
10. Detre KM, Holmes DR, Holubkov R, Cowley MJ, Bourassa MG, Faxon DP et al. Incidence and consequences of periprocedural occlusion: the 1985-1986 National Heart, Lung and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1990;82:739-50.
11. Reeder GS, Bryant SC, Suman VJ, Holmes DR Jr. Intracoronary thrombus: still a risk factor for PTCA failure? Cathet Cardiovasc Diagn 1995;34:191-5.
12. Zhao X-Q, Theroux P, Snapinn SM, Sax FL. Intracoronary thrombus and platelet glycoprotein Ilb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction: angiographic results from the PRISM-PLUS trial (Platelet Receptor Inhibition for Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms). PRISM-PLUS Investigators. Circulation 1999;100:l609-15.
13. Ferguson JJ, Barasch E, Wilson JM, Strony J, Wolfe MW, Schweiger MJ et al. The relation of clinical outcome to dissection and thrombus formation during coronary angioplasty. Heparin Registry Investigators. J Invas Cardiol 1995;7:2-10.
14. Violaris AG, Melkert R, Herrmann J-P, Serruys PW. Role of angiographically identifiable thrombus on long-term luminal renarrowing after coronary angioplasty: a quantitative angiographic analysis. Circulation 1996;93: 889-97.
15. Laskey M, Deutsch R, Hirshfeld J Jr, Kussmaul WG, Barnathan E, Laskey WK. Influence of heparin therapy on percutaneous transluminal coronary angioplasty outcome in patients with coronary arterial thrombus. Am J Cardiol 1990;65:179-82.
16. Schafer AI. Coagulation cascade: an overview. In: Loscalzo J, Schafer AI editors. Thrombosis and Hemorrhage. Boston: Blackwell Scientific; 1994. p. 3-12.
17. Ferguson JJ, Quinn M, Moake JL. Platelet physiology. In: Ferguson JJ, Chronos NAF, Harrington RA editors. Antiplatelet Therapy in Clinical Practice. London: Martin Dunitz; 2000. p.15-34.
18. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-9.
19. Moake JL, Turner NA, Stathopoulos NA, Nolasco L, Hellums JD. Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin. Blood 1988;71:1366-74.
20. Vane J. Inhibition of prostaglandin biosynthesis as a mechanism of action of aspirin-like drugs. Nature 1971;231:232-5.
21. Smith JB, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nature 1971;231:235-7.
22. Pedersen AK, Fitzgerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclo-oxygenase. N Engl J Med 1984;311:1206-11.
23. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994;330:1287-94.
24. Schror K. Aspirin and platelets: the antiplatelet actions of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost 1997;23:349-55.
25. Eikelboom JW, Hirsch JH, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-5.
26. Schror K. The basic pharmacology of ticlopidine and dopidogrel. Platelets 1993;4:252-61.
27. Schror K. Ticlopidine and dopidogrel. In: Ferguson JJ, Chronos NAF, Harrington RA editors. Antiplatelet Therapy in Clinical Practice. London: Martin Dunitz; 2000. p. 93-113.
28. Ferguson JJ. Clopidogrel. In: Braunwald E editor. Harrison's Advances in Cardiology. New York: McGraw-Hill; 2002. p. 144-54.
29. Weber AA, Reimann S, Schror K. Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro. Br J Pharmacol 1999;126:415-20.
30. Kupfer Y, Tessler S. Ticlopidine and thrombotic thrombocytopenic pupura. N Engl J Med 1997;337:1245.
31. Bennett CL, Connors JM, Carwile JM, Moake JL, Bell WR, Tarantolo SR et al. Thrombotic thrombocytopenic purpura associated with dopidogrel. N Engl J Med 2000;342:1773-7.
32. Lefkovits J, Plow EF, Topol EJ. Platelet glygoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-9.
33. Hirsh J. Heparin. N Engl J Med 1991;324:1565-74.
34. Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low molecular weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998;114 (5 Suppl):489S-510S.
35. Erratum in: Chest 1999;115:1760.
36. Hirsch J, Fuster V. Guide to anticoagulant therapy. Part I: Heparin. Circulation 1994;89:1449-68.
37. Hirsh J, Anand SS, Halperin JL, Fuster V. Guide to anticoagulant therapy: Heparin. Circulation 2001;103:2994-3018.
38. Becker PS, Miller VT. Heparin-induced thrombocytopenia. Stroke 1989;20:1449-59.
39. Aster RH. Heparin-induced thrombocytopenia and thrombosis. New Engl J Med 1995;332:1374.
40. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Horsewood P, Roberts RS, Gent M et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-5.
41. Brieger DB, Mak K-H, Kottke-Marchant K, Topol EJ. Heparin-induced thrombocytopenia. J Am Coll Cardiol 1998;31:1449-59.
42. Fareed J, Hoppensteadt DA, Walenger JM. Current perspectives on low molecular weight heparins. Semin Thromb Heamost 1993;19:I-11.
43. Weitz J. Low-molecular-weight heparians. N Engl J Med 1997;337:688-98.
44. Young E, Wells P, Holloway S, Weitz J, Hirsh J. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Hemost 1994;71:300-4.
45. Lefkovits J, Topol E. Direct thrombin inhibitors in cardiovascular medicine. Circulation 1994;90:1522-36.
46. Becker RC, Cannon CP. Hirudin: its biology and clinical use. J Thromb Thrombolysis 1994;1:7-16.
47. The Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet 2002;359:294-302.
48. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet 1994;343:881-6.
49. Serruys PW, Herman J-PR, Simon R, Rutsch W, Bode C, Laarman GJ et al., for the HELVETICA Investigators (Hirudin in a European Trial versus Heparin in the Prevention of Restenosis after PTCA Investigators). A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995;333:757-63.
50. Bittl JA, Chaitman BR, Feit F. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report of the Bivalirudin Angioplasty Study. Am Heart J 2001;142:952-90.
51. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997;349:1422-8.
52. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revasecularization. N Eng J Med 1997;336:l689-96.
53. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349:1429-35.
54. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation 1997;96:1445-53.
55. The EPISTENT Investigators. Randomized placebo-controlled and balloon angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade: the EPISTENT investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998;352:87-92.
56. The ESPRIT investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized, placebo-controlled trial. Lancet 2000;356:2037-44.
57. Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P et al. ADMIRAL Investigators. Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-903.
58. Stone G, Grines C, Cox D, Garcia E, Tcheng JE, Griffin JJ et al.; Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-66.
59. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-87.
60. Topol E, Moliterno D, Herrmann H, Powers ER, Grines CL, Cohen DJ et al. TARGET Investigators. Do Tirofiban and ReoPro Give Similar Efficacy Trial. Comparison of two platelet glycoprotein IIIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revasecularization. N Engl J Med 2001;344:1888-94.
61. Moliterno D, Yakubov S, DiBattiste P, Herrmann HC, Stone GW, Macaya C et al. Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study. Lancet 2002;360:355-60.
62. Steinhubl S, Berger P, Mann J, Fry ET, DeLago A, Wilmer C, Topol EJ; CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20.
63. Hattersley PG. Activated coagulation time of whole blood. JAMA 1966;196:436.
64. Young JA, Kisker CT, Doty DB. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. Ann Thorac Surg 1978;26:231-40.
65. Boccara A, Benamer H, Juliard JM, Aubry P, Goy P, Himbert D, Karrillon GJ et al. A randomized trial of a fixed high dose versus weight-adjusted low-dose of intravenous heparin during coronary angioplasty. Eur Heart J 1997;18:631-5.
66. Vainer J, Fleisch M, Gunnes P, Ramamurthy S, Garachemani A, Kaufmann UP et al. Low-dose heparin for routine coronary angioplasty and stenting. Am J Cardiol 1996;78:964-6.
67. McGarry TF, Gottlieb RS, Morganroth J, Zelenkofske SL, Kasparian H, Duca PR et al. The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty. Am Heart J 1992;123:1445-51.
68. Bittl JA, Ahmed WH. Relation between abrupt vessel closure and the anticoagulant response to heparin or bivalirudin during coronary angioplasty. Am J Cardiol 1998;82:50P-6P.
69. Ferguson JJ, Dougherty KG, Gaos CM, Bush HS, Marsh KC, Leachman DR. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994;23:1061-5.
70. Narins CR, Hillegass WB, Nelson CL, Tcheng JE, Harrington RA, Phillips HR et al. Relation between activated clotting time during angioplasty and abrupt closure. Circulation 1996;93:667-71.
71. Chew DP, Bhatt DL, Lincoff M, Moliterno DJ, Brener SJ, Wolski KE et al. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation 2001;103:961-6.
72. Lincoff AM, Tcheng JE, Califf RM, Bass T, Popma JJ, Teirstein PS et al. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. Am J Cardiol 1997;79:286-91.
73. Wilson JM, Dougherty KG, Ellis KO, Ferguson JJ. Activated clotting times in acute coronary syndromes and percutaneous transluminal coronary angioplasty. Cathet Cardiovasc Diagn 1995;34:1-5.
74. Doughtery KG, Gaos CM, Bush HS, Leach DR, Ferguson JJ. Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin. Cathet Cardiovasc Diagn 1992;20:200-3.
75. Kaluski E, Krakover R, Cotter G, Hendler A, Zyssman I, Milovanov O et al. Minimal heparinization in coronary angioplasty - how much heparin is really warranted? Am J Cardiol 2000;85:953-6.
76. Denardo SJ, Davis KE, Reid PR, Tcheng JE. Efficacy and safety of minimal dose (< 1000 Units) unfractionated heparin with abciximab in percutaneous coronary intervention. Am J Cardiol 2003;91:1-5.
77. Oltrona L, Eisenberg PR, Lasala JM, Sewall DJ, Shelton ME, Winters KJ. Association of heparin-resistant thrombin activity with acute ischemic complications of coronary interventions. Circulation 1996;94:2064-71.
78. Snitzer R, Miremath YJ, Lee J, Lasala JM, Eisenberg PR, Winters KJ. Suppression of intra coronary thrombin activity by weight-adjusted heparin administration during coronary interventions. Circulation 1995;92 Suppl 1:1609.
79. Ferguson JJ. All ACTs are not created equal. Tex Heart Inst J 1992;19:1.
80. Avendano A, Ferguson JJ. Comparison of Hemochron and HemoTec activated coagulation time target values during percutaneous transluminal angioplasty. J Am Coll Cardiol 1994;23:907.
81. Aguirre FV, Topol EJ, Ferguson JJ, Blankenship JC, Gardner LH, Caracciolo EA et al., for the IMPACT-II Investigators. Effect of platelet glycoprotein (GP) IIb/IIIa antagonism with integrilin on activated clotting times during coronary interventions: results from the IMPACT-Trial. Circulation 1996;94 Suppl I:I-97.
82. Tolleson TR, O'Shea JC, Bittl JA, Hillegass WB, Williams KA, Levine G et al. Relationship between heparin anticoagulation an clinical outcomes in coronary stent intervention: observations from the ESPRIT trial. J Am Coll Cardiol 2003;41:386-93.
83. Walford CD, Midei MM, Aversano TR, Gottlieb SO, Chew PH, Siu CO et al. Heparin after PTCA: increased early complications and no clinical benefit. Circulation 1991;84:II592.
84. Tanjura L, Pinto I, Centemero M, Chaves A, Mattos L, Feres F et al. Use of heparin in coronary angioplasty: randomized trial for prevention of abrupt closure. Eur Heart J 1993;14:179.
85. Friedman HZ, Cragg DR, Glazier SM, Gangadharan V, Marsalese DL, Schreiber TL et al. Randomized prospective evaluation of prolonged versus abbreviated intravenous heparin therapy after coronary. J Am Coll Cardiol 1994;24:1214.
86. Pizzuli L, Zirbes M, Fehske W, Pfeiffer D. Omission of intravneous heparin and nitroglycerin following uncomplicated coronary angioplasty: a prospective. Circulation 1995;92:I74.
87. Granger CB, Miller JM, Bovill EG, GA, Gruber A, Tracy RP, Krucoff MW et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995;91:1929-35.
88. Gabliani G, Deligonul U, Kern MJ, Vandormael M. Acute coronary occlusion occurring after successful percutaneous transluminal coronary angioplasty: temporal relationship to discontinuation of anticoagulation. Am Heart J 1988;116:696-700.
89. MacDonald LA, Myers S, Bennett CL, Fintel D, Grosshans N, Syegco R et al. Post cardiac catheterization access site complications and low-molecular-weight heparin following cardiac catheterization. J Invas Cardiol 2003;15:60-2.
90. Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia EJ et al. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double blind, unfractional heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation. J Am Coll Cardiol 1996;28:1437-43.
91. Kereiakes DJ, Grines C, Fry E, Esente P, Hoppensteadt D, Midei M et al. NICE 1 and NICE 4 Investigators. National Investigators Collaborating on Enoxaparin. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol 2001;14:272-8.
92. Ferguson JJ, Antman EM, Bates ER, Cohen M, Every NR, Harrington RA et al., The NICE-3 Investigators. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: Final results of the NICE-3 study. Am Heart J 2003;146:628-34.
93. Kereiakes DJ, Kleiman NS, Fry E, Mwawasi G, Lengerich R, Maresh K et al. Dalteparin in combination with abciximab during percutaneous coronary intervention. Am Heart J 2001;141:348-52.
94. Collet JP, Montalescot G, Lison L, Choussat R, Ankri A, Drobinski G et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001;103:658-63.
95. Bhatt DL, Lee BI, Casterella PJ, Pulsipher M, Rogers M, Cohen M et al. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 2003;41:20-5.
96. Choussat R, Montalescot G, Collet JP, Vicaut E, Ankiri A, Gallois V et al. A unique, low dose of intravenous enoxaparin in elective percutaneous intervention. J Am Coll Cardiol 2002;40:1943-50.
97. Faxon DP, Spiro TE, Minor S, Coté G, Douglas J, Gottlieb R, Califf R et al. Low molecular weight heparin in prevention of restenosis after angioplasty. Circulation 1994;90:908-14.
98. Rabah MM, Premmereur J, Graham M, Fareed J, Hoppensteadt DA, Khurana S et al. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol 1999;84:1391-5.
99. Diez JG, Lievano MJ, Croitoru M, Olaya CA, Ferguson JJ. Enoxaparin anticoagulation for percutaneous coronary interventions: a pilot safety study. Circulation 1999;100 Suppl I:I-188.
100. Moliterno DJ, Hermiller JB, Kereiakes DJ, Yow E, Applegate RJ, Braden GA et al. A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention: results of the Evaluating Enoxapatin Clottiing Times (ELECT) Study. J Am Coll Cardiol 2003;42:1132-9.
101. Henry TD, Satran D, Knox LL, Iacarella CL, Laxson DD, Antman EM. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin? Am Heart J 2001;142:590-3.
102. Schooley CC, Gilbert JH, Harlan M, Bracey A, Coulter S, Wilson JM. Kinetics of intravenously administered dalteparin. J Am Coll Cardiol 2003;41:25A.
103. Marmur JD, Anand SX, Bagga RS, Fareed J, Pan C-M, Sharma SK et al. The activated clotting time can be used to monitor the low molecular weight heparin Dalteparin after intravenous administration. J Am Coll Cardiol 2003;41:394-402.
104. Martin JL, Fry ET, Serano A. Pharmacokinetic study of enoxaparin in patients undergoing coronary intervention after treatment with subcutaneous enoxaparin in acute coronary syndromes: The PEPCI study. Eur Heart J 2001;22 Suppl:14.
105. Antman EM, Louwerenburg HW, Baars HF, Wesdorp JCL, Hamer B, Bassand J-P et al. for the ENTIRE-TIMI 23 Investigators. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction. Results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 2002;105:1642-9.
106. Fox KAA, Poole-Wilson PA, Henderson RA, Clayton TC, Chamberlain DA, Shaw TRD, et al. for the Randomization Intervention Trial of Unstable Angina (RITA) Investigators. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Lancet 2002;360:743-51.
107. Dubois C, Belmans A, Armstrong P, Grander C, Wallentin L, Van de Werf F, the ASSENT-3 Investigators. Outcome of elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab. J Am Coll Cardiol 2003;42:1178-85.
108. Mukherjee D, Mahaffey KW, Moliterno DJ, Harrington RA, Yadav JS, Pieper KS et al. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). Am Heart J 2002;144:995-1002.
109. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S et al. SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004;292:45-54.
110. Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM et al., for the ARG-911 Study Investigators. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103:1838-43.
111. Bittl JA, Strony J, Blinker JA, Ahmed WH, Meckel CR, Chaitman BR et al., for the Hirulog Angioplasty Study Investigators. Treatment of bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995;333:764-9.
112. Lincoff AM, Kleiman NS, Kottke-Marchant K, Maierson ES, Maresh K, Wolski KE et al. Bivalirudin with planned or provisional abciximab versus low dose heparin and abciximab during percutaneous coronary revascularization. Am Heart J 2002;143:847-53.
113. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289:853-63.
114. Erratum in: JAMA 2003;289:1638.
115. Lincoff A, Kleiman N, Kereiakes D, Feit F, Bittl JA, Jackman JD et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2. JAMA 2004;292:696-703.
116. Cohen D, Lincoff A, Lavelle T, Chen HL, Bakhai A, Berezin RH et al. Economic evaluation of bivalirudin with provisional glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for percutaneous coronary intervention. J Am Coll Cardiol 2004;44:1792-800.
117. Peters R, Mehta S, Fox K, Zhao F, Lewis BS, Kopecky SL et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003;108:1682-7.
118. Mehta S, Yusuf S, Peters R, Bertrand ME, Lewis BS, Natarajan MK et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33.
119. Kastrati A, Mehilli J, Schuhlen H, Dirschinger J, Dotzer F, ten Berg JM et al.; Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study Investigators. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004;350:232-8.
120. Kastrati A, Beckerath N, Joost A, Pogatsa-Murray G, Gorchakova O, Schomig A. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidigrel therapy. Circulation 2004;110:1916-9.
121. Mehilli J, Kastrati A, Schuhlen H, Dibra A, Dotzer F, von Beckerath N et al.; Intracoronary Stenting and Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics (ISAR-SWEET) Study Investigators. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 2004;110:3027-35.
122. O'Shea J, Hafley G, Greenberg S, Hasselblad V, Lorenz TJ, Kitt MM et al.; ESPRIT Investigators. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial; a randomized controlled trial. JAMA 2001;285:2468-73.
123. Blazing MA, de Lemos JA, White HD, Fox KAA, Verheugt FWA, Ardissino D et al. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA 2004;292:55-64.
124. Goodman SG, Fitchett D, Armstrong PW, Tan M, Langer A. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 2003;107:238-44.